Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns
The DOI matches its Crossref record.
Abstract
The European Medicines Agency (EMA) has recommended the refusal of a marketing authorisation for Alzheimer’s disease drug aducanumab (Aduhelm) because of a lack of evidence that itwillwork and concerns over safety.1 Theagency’s Committee forMedicinal Products forHumanUse (CHMP)published its opinionon 16December, six months after the drug was controversially approved through a fast track pathway in the US2 despite major concerns over the evidence base.3 In its announcement, theEMAsaid althoughaducanumab reduces amyloidbeta in thebrain “the linkbetween this effect and clinical improvement had not been established,” with conflicting trial results that did not show the drug was effective at treating adults with early stage Alzheimer’s disease. It alsohighlighted that brain scans of somepatients showed “abnormalities suggestive of swelling or bleeding, which could potentially cause harm.”This comes after researchers reported that over 40%of trial participants who had a high dose (10 mg/kg) of aducanumab experienced brain swelling or bleeding.4 Last year, the US Food and Drug Administration (FDA) advisory committee recommended that the drug, which costs $56 000 (£42 000; €49 000) per patient per year, should not be approved. They concluded that there was not enough evidence to suggest that the drug would result in cognitive improvement. Three members of the advisory panel resigned after the FDA decided to approve the drug anyway.5 Manufacturer Biogen has said it will ask for CHMP to re-examine the case within the allowed 15 days. The final decision on marketing authorisation will be made by the European Commission. Commenting on the decision, Richard Oakley, associate director of research at Alzheimer’s Society, said, “It will be disappointing for people with dementia to hear today’s decision on aducanumab. There have been no new treatments for Alzheimer’s disease in a long time, but that makes it even more important any new drugs for dementia have the data to back up that they’re both safe and effective. Aducanumab may be the first drug that aims to slow down Alzheimer’s disease to reach this stage, but it’s certainly not the last—there are 125 other drugs currently in clinical trials.”
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 267
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review
Pozzi, F. E., Conti, E., Appollonio, I., Ferrarese, C., & Tremolizzo, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.998224 · Cited by 36
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
Metadata
- Authors
- Mahase, E.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-12-20
- Volume
- 375
- Pages
- n3127
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4200405478
- Cited by
- 47
- References
- 0
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns. https://app.cochat.ai/papers/10.1136/bmj.n3127
- The paper
- Mahase, E. (2021). Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns. BMJ. https://doi.org/10.1136/bmj.n3127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.